Biotech Prediction Bets on Trials Prompt Ethical Backlash
TL;DR
Kalshi’s plan to let users bet on the outcomes of clinical trials has drawn sharp ethical objections from researchers and patients who warn such markets could undermine trial integrity and patient welfare, even as Kalshi argues bets would reflect updated evidence and cut through hype. The controversy highlights broader concerns about gamifying lifesaving research and treating trials as speculative bets, rather than purely scientific endeavors.
Topics:businesstechnology#biotech#clinical-trials#drug-development#ethics#prediction-markets#technology
- Kalshi Defends Plan to Bet on Lives of Cancer Patients Futurism
- Kalshi and Polymarket bets on clinical trials criticized as 'ghastly' NPR
- My son has cancer. Kalshi wants you to be able to bet on his medical future | Joshua Pederson The Guardian
- Opinion: Should you be allowed to bet on wars, fires and drug approvals? Deseret News
- Pour a Scotch, we’re talking clinical trials and prediction markets The Cancer Letter
Want the full story? Read the original reporting
Read on Futurism